CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. (scientific article published on 04 December 2008)

The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation

Q24290417

CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling

Q24300048

Casein kinase 2 Is activated and essential for Wnt/beta-catenin signaling

Q28238154

PTEN1 is frequently mutated in primary endometrial carcinomas

Q28250937

Mechanism of protein kinase CK2 association with nuclear matrix: role of disulfide bond formation

Q28575901

CK2 controls the recruitment of Wnt regulators to target genes in vivo

Q33264011

Nuclear matrix and protein kinase CK2 signaling

Q33826094

Protein kinase CK2 signal in neoplasia

Q34238490

Molecular pathology of endometrial hyperplasia and carcinoma

Q34296260

Joining the cell survival squad: an emerging role for protein kinase CK2.

Q34682686

Protein kinase CK2: structure, regulation and role in cellular decisions of life and death

Q34978734

Deletion mapping on chromosome 10q25-q26 in human endometrial cancer

Q36136415

CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.

Q40056601

Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells

Q40314290

Significance of the casein kinase system in cell growth and proliferation with emphasis on studies of the androgenic regulation of the prostate.

Q40396123

FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis

Q40428505

Protein kinase CK2 phosphorylates and upregulates Akt/PKB.

Q40437202

Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities

Q40485163

Nuclear matrix as an anchor for protein kinase CK2 nuclear signalling

Q41141478

Endometrial neoplasia: prognostic significance of ploidy status

Q41156493

Casein kinase II is required for transition of G0/G1, early G1, and G1/S phases of the cell cycle.

Q41481492

Protein kinase CK2: signaling and tumorigenesis in the mammary gland

Q42516839

A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells

Q43509456

Protein kinase CK2 in mammary gland tumorigenesis

Q43652205

Cyclin D1 gene (CCND1) mutations in endometrial cancer

Q44573130

Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma.

Q45104153

The regulatory beta-subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis.

Q45744379

PTEN/MMAC1 mutations in endometrial cancers.

Q53439663

Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle.

Q53466012

Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3.

Q53669937

Characterization of casein kinase II in human colonic carcinomas after heterotransplantation into nude mice

Q69717477

Cell biological studies with monoclonal and polyclonal antibodies against human casein kinase II subunit beta demonstrate participation of the kinase in mitogenic signaling

Q70550525

Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate

Q71607033

Role of Protein Phosphorylation in Post-translational Regulation of Protein B23 during Programmed Cell Death in the Prostate Gland

Q72054829

Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers

Q72187171

Androgenic regulation of phosphorylation and stability of nucleolar protein nucleolin in rat ventral prostate

Q72777303

Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells

Q73112026

PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases

Q73622060

Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies

Q73722520

CTNNB1 mutations and beta-catenin expression in endometrial carcinomas

Q77951578

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

apoptotic process

Q14599311

endometrial carcinoma

Q18555222

P304

page(s)

287-296

P577

publication date

2008-12-04

P1433

published in

The American Journal of Pathology

Q4744259

P1476

title

CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation

P478

volume

174

Reverse relations

cites work (P2860)

Q43252750	A FRET-based microplate assay for human protein kinase CK2, a target in neoplastic disease
Q28543105	A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases
Q33882422	A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis.
Q91785257	CD163, a novel therapeutic target, regulates the proliferation and stemness of glioma cells via casein kinase 2
Q39761676	Casein kinase 2 inhibition differentially modulates apoptotic effect of trichostatin A against epithelial ovarian carcinoma cell lines
Q37727749	Casein kinase 2 phosphorylates GluA1 and regulates its surface expression
Q42463517	DcR1 expression in endometrial carcinomas
Q34358346	Dopamine, by Acting through Its D2 Receptor, Inhibits Insulin-Like Growth Factor-I (IGF-I)-Induced Gastric Cancer Cell Proliferation via Up-Regulation of Krüppel-Like Factor 4 through Down-Regulation of IGF-IR and AKT Phosphorylation
Q37994980	Endometrial carcinoma: molecular alterations involved in tumor development and progression
Q39406462	Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia.
Q34805471	KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels
Q33936620	Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment
Q54217001	Modulated Gene Expression of Toxoplasma gondii Infected Retinal Pigment Epithelial Cell Line (ARPE-19) via PI3K/Akt or mTOR Signal Pathway.
Q38067440	Molecular pathology of endometrial carcinoma
Q34695481	Phosphorylation of the anaphase-promoting complex/Cdc27 is involved in TGF-beta signaling.
Q34353848	Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors.
Q27026335	Protein kinase CK2 and human malignant tumors
Q35070242	Protein kinase CK2 increases glutamatergic input in the hypothalamus and sympathetic vasomotor tone in hypertension.
Q34240359	SNP screening of central MHC-identified HLA-DMB as a candidate susceptibility gene for HIV-related Kaposi's sarcoma
Q36725089	The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer
Q49787856	Under-expression of CK2β subunit in ccRCC represents a complementary biomarker of p-STAT3 Ser727 that correlates with patient survival
Q37665293	Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
Q55434033	[The targets research of non-small cell lung cancer targeted therapy].